Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joshua Pankrac

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
AIDS Research and Therapy|September 13, 2017
Eradication of HIV-1 latent reservoirs through therapeutic vaccinationJoshua Pankrac, Katja Klein, Jamie F S Mann
Immunology|November 14, 2021
Blocking T-cell egress with FTY720 extends DNA vaccine expression but reduces immunogenicityJamie F S Mann, Paul F McKay, Katja Klein, et al.
Retrovirology|August 4, 2021
Addressing an HIV cure in LMICSherazaan D Ismail, Joshua Pankrac, Emmanuel Ndashimye, et al.
Journal of Virology|July 21, 2022
Enhancement of CD4 Binding, Host Cell Entry, and Sensitivity to CD4bs Antibody Inhibition Conferred by a Natural but Rare Polymorphism in the HIV-1 EnvelopeAnnette N Ratcliff, Colin M Venner, Abayomi S Olabode, et al.
NPJ Vaccines|January 26, 2018
A heterogeneous human immunodeficiency virus-like particle (VLP) formulation produced by a novel vector systemJoshua Pankrac, Katja Klein, Paul F McKay, et al.
Ebiomedicine|July 14, 2020
A targeted reactivation of latent HIV-1 using an activator vector in patient samples from acute infectionJamie F S Mann, Joshua Pankrac, Katja Klein, et al.
Emerging Microbes & Infections|March 6, 2024
Effective and targeted latency reversal in CD4<sup>+</sup> T cells from individuals on long term combined antiretroviral therapy initiated during chronic HIV-1 infectionMinh Ha Ngo, Joshua Pankrac, Ryan C Y Ho, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
AIDS Research and Therapy|September 13, 2017
Eradication of HIV-1 latent reservoirs through therapeutic vaccinationJoshua Pankrac, Katja Klein, Jamie F S Mann
Immunology|November 14, 2021
Blocking T-cell egress with FTY720 extends DNA vaccine expression but reduces immunogenicityJamie F S Mann, Paul F McKay, Katja Klein, et al.
Retrovirology|August 4, 2021
Addressing an HIV cure in LMICSherazaan D Ismail, Joshua Pankrac, Emmanuel Ndashimye, et al.
Journal of Virology|July 21, 2022
Enhancement of CD4 Binding, Host Cell Entry, and Sensitivity to CD4bs Antibody Inhibition Conferred by a Natural but Rare Polymorphism in the HIV-1 EnvelopeAnnette N Ratcliff, Colin M Venner, Abayomi S Olabode, et al.
NPJ Vaccines|January 26, 2018
A heterogeneous human immunodeficiency virus-like particle (VLP) formulation produced by a novel vector systemJoshua Pankrac, Katja Klein, Paul F McKay, et al.
Ebiomedicine|July 14, 2020
A targeted reactivation of latent HIV-1 using an activator vector in patient samples from acute infectionJamie F S Mann, Joshua Pankrac, Katja Klein, et al.
Emerging Microbes & Infections|March 6, 2024
Effective and targeted latency reversal in CD4<sup>+</sup> T cells from individuals on long term combined antiretroviral therapy initiated during chronic HIV-1 infectionMinh Ha Ngo, Joshua Pankrac, Ryan C Y Ho, et al.
Pageof 1